David Robert Bogart - 25 Sep 2026 Form 4 Insider Report for Conexeu Sciences Inc. (CNXU)

Reporting relationship: Chief Commercial Officer, Director
Issuer ticker: CNXU
Reported as of: 25 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Sep 2026, 17:38:52 UTC
Prior SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ David Bogart

Key filing fact

David Robert Bogart filed Form 4 for Conexeu Sciences Inc. (CNXU) on 28 Sep 2026.

Key facts

This page summarizes David Robert Bogart's Form 4 filing for Conexeu Sciences Inc. (CNXU).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Sep 2026, 17:38.

Change

Previous filing in this sequence was filed on 11 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002128417 Primary reporting owner

Bogart David Robert

Relationship: Chief Commercial Officer, Director
Address: 50 WEST LIBERTY STREET, SUITE 880, RENO
Signature: /s/ David Bogart
Signature date: 28 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNXU transaction

Common Stock

Options Exercise

Transaction value
Shares: +750,000
Change %: +71%
Price: $0.001000^*
Shares after: 1,812,500
Date: 25 Sep 2026
Ownership: Direct
Footnotes: F1

CNXU holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 431,250
Date: 25 Sep 2026
Ownership: By 0865546 B.C. Ltd.
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNXU transaction Derivative

Performance Warrants

Options Exercise

Transaction value
Shares: -750,000
Change %: -75%
Price: $0.000000^*
Shares after: 250,000
Date: 25 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 750,000
Exercise price: $0.001000
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

Footnote F2

Held by 0865546 B.C. Ltd., over which the Reporting Person has sole voting and dispositive power.

Footnote F3

The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.